Should the FDA be requiring a Risk Evaluation and Mitigation Strategy for mifepristone? - Ep 147
Nov 11, 2024•18 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Explore the basis for and controversy surrounding the US Food and Drug Administration requiring a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Full text of the manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2034.
For the best experience, listen in Metacast app for iOS or Android